Follow-Up
On the day of randomization, all antianginal medications initiated in the pre-randomization period were stopped. Patients entered the 12-week blinded follow-up phase, with continued daily smartphone application symptom reporting. During this period, antianginal medication initiation and uptitration was triggered by patient contact and managed by staff blinded to study group allocation, using an identical protocol to the pre-randomization phase.At the end of the blinded follow-up period, patients returned for exercise stress test, dobutamine stress echo and symptom and quality of life questionnaires. After test completion, patients and research and medical teams were unblinded. This marked the end of the study. Patients returned to usual clinical care. Any actions or decisions after unblinding did not contribute to study end point data.